FDA Staff Push Back on HHS Plan to Expand Peptide Access

A recent initiative by the Department of Health and Human Services (HHS) aims to broaden public access to certain unproven peptide drugs. This policy met substantial resistance from most Food and Drug Administration (FDA) scientific personnel, who raised significant safety concerns.

The controversial directive, posted online, specifically permits specialty pharmacies to dispense several injectable peptides. These compounds are often promoted for enhancing muscle growth, accelerating injury recovery, and boosting overall energy levels.

Such a leading role for HHS in regulating compounding pharmacies is highly atypical, as the FDA traditionally oversees this domain. The agency significantly tightened its scrutiny of compounded drugs following a deadly fungal meningitis outbreak in 2012.

HHS ultimately pivoted from its initial intent to formally regulate these peptides as safe, given the FDA’s strong scientific objections. Consequently, the current policy merely instructs the FDA not to enforce existing rules against pharmacies compounding these unapproved substances.

Despite the agency's overarching concerns, FDA staffers did contribute technical assistance, integrating vital safety guardrails into the final plan. These measures mandate ingredient sourcing from registered facilities and require data collection on potential adverse effects.